Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities

References

• Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(19):3159–3165.
   PubMed Web of Science ®Google Scholar
• Linschoten M, Kamphuis JAM, van Rhenen A, et al. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and Meta-analysis. Lancet Haematol. 2020;7(4):e295–e308.
   PubMed Web of Science ®Google Scholar
• Baech J, Hansen SM, Lund PE, et al. Cumulative anthracycline exposure and risk of cardiotoxicity; a danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines. Br J Haematol. 2018;183(5):717–726.
   PubMed Web of Science ®Google Scholar
• Boddicker NJ, Larson MC, Castellino A, et al. Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. Am J Hematol. 2021;96(8):979–988.
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–2879.
   PubMed Web of Science ®Google Scholar
• Qin A, Thompson CL, Silverman P. Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin. J Cancer Surviv. 2015;9(2):252–259.
   PubMed Web of Science ®Google Scholar
• Moccia AA, Schaff K, Freeman C, et al. Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines. Blood Adv. 2021;5(5):1483–1489.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–1861.
   PubMed Web of Science ®Google Scholar
• Wieringa A, Boslooper K, Hoogendoorn M, et al. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol. 2014;165(4):489–496.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Miura K, Hojo A, et al. Charlson comorbidity index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2011;137(7):1079–1084.
   PubMed Web of Science ®Google Scholar
• Moccia A, Schaff K, Hoskins P, et al. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines. Blood. 2009;114:408.
   Web of Science ®Google Scholar
• Morrison VA, Hamilton L, Ogbonnaya A, et al. Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma - Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: a humedica database retrospective cohort analysis, 2007–2015. J Geriatr Oncol. 2020;11(1):41–54.
   PubMed Web of Science ®Google Scholar
• Juul MB, Jensen PH, Engberg H, et al. Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: a danish population-based cohort study. Eur J Cancer. 2018;99:86–96.
   PubMed Web of Science ®Google Scholar
• Lin RJ, Behera M, Diefenbach CS, et al. Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. Blood. 2018;131(9):1037.
   PubMed Web of Science ®Google Scholar
• Ferraro MP, Gimeno-Vazquez E, Subirana I, et al. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification. Eur J Haematol. 2019;102(6):509–515.
   PubMed Web of Science ®Google Scholar
• Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893–911.
   PubMed Web of Science ®Google Scholar
• Abdel-Qadir H, Ong G, Fazelzad R, et al. Interventions for preventing cardiomyopathy due to anthracyclines: a bayesian network Meta-analysis. Ann Oncol. 2017;28(3):628–633.
   PubMed Web of Science ®Google Scholar
• Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left ventricular dysfunction with enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355–2362.
   PubMed Web of Science ®Google Scholar
• Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology study group of the heart failure association of the european society of cardiology in collaboration with the international Cardio-Oncology society. Eur J Heart Fail. 2020;22(11):1945–1960.
   PubMed Web of Science ®Google Scholar
• Prusila REI, Peroja P, Jantunen E, et al. Treatment of diffuse large B-cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP-16). Hematol Oncol. 2019;37(2):136–142.
   PubMed Web of Science ®Google Scholar
• Rashidi A, Oak E, Carson KR, et al. Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by hans criteria. Leuk Lymphoma. 2016;57(5):1191–1193.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460–468.
   PubMed Web of Science ®Google Scholar
• Rigacci L, Annibali O, Kovalchuk S, et al. Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. Hematol Oncol. 2020;38(4):478–486.
   PubMed Web of Science ®Google Scholar
• Sancho JM, Fernández-Alvarez R, Gual-Capllonch F, et al. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the spanish GELTAMO group. Cancer Med. 2021;10(4):1314–1326.
   PubMed Web of Science ®Google Scholar
• Fridrik MA, Jaeger U, Petzer A, et al. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: a randomised phase-III study from the Austrian cancer drug therapy working group [arbeitsgemeinschaft medikamentöse tumortherapie AGMT](NHL-14). Eur J Cancer. 2016;58:112–121.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Wilson WH, Jung SH, et al. Dose-Adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-Cell lymphoma: Clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–1799.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017–3024.
   PubMed Web of Science ®Google Scholar
• Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394(10216):2271–2281.
   PubMed Web of Science ®Google Scholar
• Fields PA, Townsend W, Webb A, et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom national cancer research institute trial. J Clin Oncol. 2014;32(4):282–287.
   PubMed Web of Science ®Google Scholar
• Shen QD, Zhu HY, Wang L, et al. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial. Lancet Haematol. 2018;5(6):e261–e9.
   PubMed Web of Science ®Google Scholar
• Olszewski A, Avigdor A, Babu S, et al. Single-Agent mosunetuzumab is a promising safe and efficacious Chemotherapy-Free regimen for elderly/unfit patients with previously untreated diffuse large B‑cell lymphoma. Blood. 2020;136:43–45.
   Web of Science ®Google Scholar
• Melani C, Lakhotia R, Pittaluga S, et al. Phase 1b/2 study of vipor (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in relapsed/refractory B-Cell lymphoma: Safety, efficacy and molecular analysis. 2020;136(Supplement 1):44–45.
   Google Scholar
• Westin JR, Nastoupil JL, Fayad L, et al. Smart start: Rituximab, lenalidomide, and ibrutinib alone and in combination with standard chemotherapy for patients with newly diagnosed diffuse large B-Cell lymphoma: Final phase II results. Blood. 2019;1581.
   Google Scholar